Tags

Type your tag names separated by a space and hit enter

Autoantibodies to tissue transglutaminase in Sjögren's syndrome and related rheumatic diseases.
J Rheumatol 2003; 30(12):2613-9JR

Abstract

OBJECTIVE

Sjögren's syndrome (SS) has been reported in up to 15% of patients with biopsy proven celiac disease (CD). The diagnosis of CD in the setting of SS and other systemic rheumatic diseases can be difficult because they are often associated with a number of gastrointestinal symptoms and diseases. Although the diagnosis of CD is often confirmed by a small bowel biopsy, marker autoantibodies directed against the endomysium of transitional epithelium (EMA) and tissue transglutaminase (tTG) are highly correlated with biopsy-proven disease and serve as a valuable screening test. We used an IgA-anti-tissue transglutaminase antibody (anti-tTG) ELISA to assess the prevalence of anti-tTG in an unselected cohort of patients with SS and other systemic rheumatic diseases.

METHODS

Sera from 50 patients with SS, 50 with systemic lupus erythematosus (SLE), 50 with rheumatoid arthritis (RA), 30 with systemic sclerosis (SSc), and 50 healthy controls were tested for autoantibodies to tTG. A comparison group of 40 sera from patients with biopsy-confirmed CD was also included. IgA anti-tTG was measured by a commercially available ELISA kit (Inova, San Diego, CA) that employs purified tTG.

RESULTS

Six of the 50 (12%) IgA sufficient SS patients had anti-tTG compared to 2 (4%) normal sera, 3 (6%) SLE, 2 (7%) SSc, and 1 (2%) RA. By comparison, in the CD cohort, 33 (83%) had anti-tTG. Five of 6 SS patients with anti-tTG had symptoms, signs, or small bowel biopsy findings consistent with a diagnosis of CD. IgA anti-tTG and EMA were accompanied by other IgA autoantibodies in SS sera.

CONCLUSION

Anti-tTG ELISA is a reliable method to indicate a coexisting diagnosis of CD in patients with SS. Interestingly, the frequency of false positive tTG tests in any of the systemic rheumatic diseases is not significantly greater than in controls. Further, our study shows that anti-tTG is more prevalent in SS than in other systemic rheumatic diseases. The tTG ELISA may be used as a screening test to identify patients with SS who are at risk and require further evaluation for the presence of CD.

Authors+Show Affiliations

Department of Medicine, Faculty of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, Canada T2N 4N1.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

14719202

Citation

Luft, Leeanne M., et al. "Autoantibodies to Tissue Transglutaminase in Sjögren's Syndrome and Related Rheumatic Diseases." The Journal of Rheumatology, vol. 30, no. 12, 2003, pp. 2613-9.
Luft LM, Barr SG, Martin LO, et al. Autoantibodies to tissue transglutaminase in Sjögren's syndrome and related rheumatic diseases. J Rheumatol. 2003;30(12):2613-9.
Luft, L. M., Barr, S. G., Martin, L. O., Chan, E. K., & Fritzler, M. J. (2003). Autoantibodies to tissue transglutaminase in Sjögren's syndrome and related rheumatic diseases. The Journal of Rheumatology, 30(12), pp. 2613-9.
Luft LM, et al. Autoantibodies to Tissue Transglutaminase in Sjögren's Syndrome and Related Rheumatic Diseases. J Rheumatol. 2003;30(12):2613-9. PubMed PMID: 14719202.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Autoantibodies to tissue transglutaminase in Sjögren's syndrome and related rheumatic diseases. AU - Luft,Leeanne M, AU - Barr,Susan G, AU - Martin,Liam O, AU - Chan,Edward K L, AU - Fritzler,Marvin J, PY - 2004/1/14/pubmed PY - 2004/3/31/medline PY - 2004/1/14/entrez SP - 2613 EP - 9 JF - The Journal of rheumatology JO - J. Rheumatol. VL - 30 IS - 12 N2 - OBJECTIVE: Sjögren's syndrome (SS) has been reported in up to 15% of patients with biopsy proven celiac disease (CD). The diagnosis of CD in the setting of SS and other systemic rheumatic diseases can be difficult because they are often associated with a number of gastrointestinal symptoms and diseases. Although the diagnosis of CD is often confirmed by a small bowel biopsy, marker autoantibodies directed against the endomysium of transitional epithelium (EMA) and tissue transglutaminase (tTG) are highly correlated with biopsy-proven disease and serve as a valuable screening test. We used an IgA-anti-tissue transglutaminase antibody (anti-tTG) ELISA to assess the prevalence of anti-tTG in an unselected cohort of patients with SS and other systemic rheumatic diseases. METHODS: Sera from 50 patients with SS, 50 with systemic lupus erythematosus (SLE), 50 with rheumatoid arthritis (RA), 30 with systemic sclerosis (SSc), and 50 healthy controls were tested for autoantibodies to tTG. A comparison group of 40 sera from patients with biopsy-confirmed CD was also included. IgA anti-tTG was measured by a commercially available ELISA kit (Inova, San Diego, CA) that employs purified tTG. RESULTS: Six of the 50 (12%) IgA sufficient SS patients had anti-tTG compared to 2 (4%) normal sera, 3 (6%) SLE, 2 (7%) SSc, and 1 (2%) RA. By comparison, in the CD cohort, 33 (83%) had anti-tTG. Five of 6 SS patients with anti-tTG had symptoms, signs, or small bowel biopsy findings consistent with a diagnosis of CD. IgA anti-tTG and EMA were accompanied by other IgA autoantibodies in SS sera. CONCLUSION: Anti-tTG ELISA is a reliable method to indicate a coexisting diagnosis of CD in patients with SS. Interestingly, the frequency of false positive tTG tests in any of the systemic rheumatic diseases is not significantly greater than in controls. Further, our study shows that anti-tTG is more prevalent in SS than in other systemic rheumatic diseases. The tTG ELISA may be used as a screening test to identify patients with SS who are at risk and require further evaluation for the presence of CD. SN - 0315-162X UR - https://www.unboundmedicine.com/medline/citation/14719202/Autoantibodies_to_tissue_transglutaminase_in_Sjögren's_syndrome_and_related_rheumatic_diseases_ L2 - http://www.jrheum.org/cgi/pmidlookup?view=long&pmid=14719202 DB - PRIME DP - Unbound Medicine ER -